The efficacy of trabectedin in treating ovarian cancer.

about

Prediction of therapy response in ovarian cancer: Where are we now?A drug development perspective on targeting tumor-associated myeloid cells.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.

P2860

Q39263260-F8B8FE35-8E1F-4B90-A791-951CE9E64586 Q48652546-40A891E4-663A-48B3-88F2-E9BE2448A60C Q55365628-85D85917-820F-47FC-ADFE-2BEEC16EF861

P2860

The efficacy of trabectedin in treating ovarian cancer.

Item

http://www.wikidata.org/entity/Q38763841

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The efficacy of trabectedin in treating ovarian cancer.

@en

type

Item

label

The efficacy of trabectedin in treating ovarian cancer.

@en

prefLabel

The efficacy of trabectedin in treating ovarian cancer.

@en

P1476

The efficacy of trabectedin in treating ovarian cancer.

@en

P2093

Eleonora Teplinsky

http://www.w3.org/2001/XMLSchema#string

Thomas J Herzog

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.

P304

313-323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1285282

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28140689

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

The efficacy of trabectedin in treating ovarian cancer.

about

P2860

P2860

The efficacy of trabectedin in treating ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921